
Drug news
US development of GCS 100 discontinued in Chronic Kidney Disease-La Jolla Pharma
La Jolla Pharma has decided to discontinue development of its polysaccharide-based galectin-3 inhibitor GCS-100 for Chronic Kidney Disease. This is due to the challenge of regulatory requirements - in particular the FDA has indicated that the Company would be required to conduct additional chemical characterization of GCS-100 prior to further clinical development. The Company believes that the timeframe and ultimate success of developing analytical methods that would satisfy the FDA's requirements are highly uncertain.